UnitedHealth (UNH) AI Stock Analysis

• Market Cap: $258.84B
• Dividend Yield: 2.69%
• Average Volume (3M): 11.16M
• Price to Earnings (P/E): 24.9
• Beta (1Y): 0.12
• Revenue Growth: 10.48%
• EPS Growth: 24.25%
• Country: US
• Employees: 400,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Plans
• EPS (TTM): 2.11
• Shares Outstanding: 907,675,840
• 10 Day Avg. Volume: 8,345,916
• 30 Day Avg. Volume: 11,160,123
• PEG Ratio: -1.62
• Price to Book (P/B): 3.19
• Price to Sales (P/S): 0.67
• P/FCF Ratio: 18.69
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: 0.70
• Enterprise Value/Gross Profit: 3.77
• Enterprise Value/Ebitda: 13.57
• 1Y Price Target: $368.50
• Price Target Upside: 29.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19
• EPS Forecast (FY): 17.85
• Revenue Forecast (FY): $441.73B

• Rating: 63 Neutral
• Price Target: $304.00 ▲(6.60% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

UNH scores as moderately attractive: strong scale and cash flow support the fundamentals, and management guided to EPS growth with planned efficiency and margin actions. The score is held back by clear profitability compression, meaningful 2026 membership declines and cost-trend headwinds, plus currently bearish technicals.

Positive Factors

Strong cash generation

UnitedHealth's very strong 2025 cash generation (sharp OCF rebound and large FCF) provides durable financial flexibility. High cash conversion supports reinvestment in Optum, funding for AI/tech, and the ability to reduce leverage or resume capital returns without relying on volatile earnings.

Scale and diversified revenue base

Sustained multiyear top-line growth evidences a broad, diversified business mix (UnitedHealthcare plus Optum) providing bargaining power with providers and manufacturers. Scale underpins stable premium flows, TB care volumes, and cross-selling of Optum services, buffering the company against industry cycles.

Optum tech, AI and operating efficiency initiatives

Material, ongoing investments in AI and consolidation of systems (EMR standardization, call automation) create a structural efficiency runway. If executed, these initiatives can sustainably lower unit costs, expand Optum margins, and strengthen a technical moat in care coordination and pharmacy services.

Negative Factors

Large 2026 membership contraction

A multi-million member decline materially reduces premium volume and dilutes fixed-cost absorption. This structural membership falloff weakens underwriting scale, can raise unit medical costs, and forces product repricing or footprint changes that may take multiple quarters to restore margins and revenue synergies.

Sustained margin compression

Meaningful, persistent margin erosion reduces earnings sensitivity to revenue growth and compresses return on capital. Restoring historical margins requires both medical cost control and Optum margin recovery; until execution proves durable, profitability remains structurally lower and more sensitive to funding and utilization shifts.

Rising debt and restructuring-related liabilities

Higher absolute debt levels and recent Optum-related charges raise leverage risk and limit near-term capital flexibility. Increased debt plus restructuring obligations can constrain investment optionality, slow share repurchases, and make achieving long-term capital targets dependent on sustained cash flow improvement.

UnitedHealth Business Overview & Revenue Model

Company Description

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.

How the Company Makes Money

UnitedHealth Group generates revenue primarily through its health insurance offerings and health services. The UnitedHealthcare segment earns revenue from premiums paid by individuals and employers for health plans, as well as from government programs like Medicare and Medicaid. Optum contributes significantly to the company's revenue through its pharmacy care services, where it manages prescription drug benefits and retail pharmacy operations, and through its health services that focus on data analytics and care management. Key revenue streams include premium revenues, service fees, and the management of pharmacy benefit plans. Additionally, strategic partnerships with employers, healthcare providers, and government agencies enhance its service offerings and revenue potential, while investments in technology and analytics help drive efficiencies and improve care outcomes.

UnitedHealth Financial Statement Overview

Summary

Strong multi-year revenue growth and standout cash generation (2025 operating cash flow $38.3B; free cash flow $32.0B with high conversion vs. net income) support a solid base. Offsetting this, profitability and returns have clearly compressed since 2023 (2025 net margin ~3.2% vs ~6% prior), and debt has risen materially over time, making the outlook more execution-dependent.

Income Statement

Revenue has compounded strongly over the last several years (from $257.1B in 2020 to $447.6B in 2025), indicating durable demand and scale. However, profitability has compressed meaningfully: gross margin fell to 18.5% in 2025 from ~22–26% in prior years, and net margin declined to 3.2% in 2025 from ~6.0–6.2% in 2020–2023. Net income was essentially flat versus 2024 ($14.2B vs. $14.4B) and well below 2022–2023 levels, reflecting weaker earnings conversion despite continued top-line growth.

Balance Sheet

The balance sheet is supported by a sizable equity base ($100.1B in 2025) and growing assets ($309.6B). Leverage is moderate for a large insurer, with debt-to-equity around 0.78 in 2025 (roughly in line with recent years), but total debt has risen notably over time ($43.5B in 2020 to $78.4B in 2025). Returns on equity remain solid (14.2% in 2025), though they have stepped down from the stronger 2021–2023 range (~24–26%), consistent with the recent profitability pressure.

Cash Flow

Cash generation is a key strength: operating cash flow rebounded sharply to $38.3B in 2025 from $24.2B in 2024, and free cash flow rose to $32.0B. Free cash flow growth was very strong in 2025 (+84%), and free cash flow covered a large portion of net income (about 84% in 2025, consistently ~85–91% across the period), suggesting high-quality earnings and strong cash conversion. A watch item is that cash flow relative to revenue remains modest (operating cash flow at ~33% of revenue in 2025 based on the provided ratio), even though it improved versus 2024.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	447.57B	400.28B	371.62B	324.16B	287.60B
Gross Profit	82.92B	89.40B	90.96B	79.62B	69.65B
EBITDA	23.06B	28.08B	36.33B	31.84B	27.07B
Net Income	12.06B	14.40B	22.38B	20.12B	17.29B
Balance Sheet
Total Assets	309.58B	298.28B	273.72B	245.71B	212.21B
Cash, Cash Equivalents and Short-Term Investments	28.12B	29.11B	29.63B	27.91B	23.91B
Total Debt	78.39B	76.90B	67.44B	57.62B	46.00B
Total Liabilities	207.88B	195.69B	174.80B	159.36B	135.73B
Stockholders Equity	94.11B	92.66B	88.76B	77.77B	71.76B
Cash Flow
Free Cash Flow	16.07B	20.70B	25.68B	23.40B	19.89B
Operating Cash Flow	19.70B	24.20B	29.07B	26.21B	22.34B
Investing Cash Flow	-8.69B	-20.53B	-15.57B	-28.48B	-10.37B
Financing Cash Flow	-11.64B	-3.51B	-11.53B	4.23B	-7.46B

UnitedHealth Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 285.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNH, the sentiment is Negative. The current price of 285.17 is above the 20-day moving average (MA) of 283.88, below the 50-day MA of 305.76, and below the 200-day MA of 310.23, indicating a neutral trend. The MACD of -4.02 indicates Negative momentum. The RSI at 45.71 is Neutral, neither overbought nor oversold. The STOCH value of 53.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNH.

UnitedHealth Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELV	64 Neutral	$61.96B	13.73	13.01%	1.99%	11.96%	-11.11%
UNH	63 Neutral	$258.84B	24.92	12.70%	2.69%	10.48%	24.25%
CNC	56 Neutral	$21.30B	―	-27.74%	―	14.92%	-286.72%
CVS	55 Neutral	$99.56B	56.87	2.34%	3.41%	6.71%	-90.11%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOH	49 Neutral	$7.52B	18.68	10.99%	―	13.71%	-18.02%
HUM	47 Neutral	$21.53B	-9.68	6.59%	1.38%	9.87%	-5.58%

UnitedHealth Corporate Events

UnitedHealth to Present at Barclays Global Healthcare Conference

UnitedHealth Group said senior leaders will participate in an interview-style session at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 11:30 a.m. Eastern Time. The discussion will cover the company’s strategy, market positions, recent performance and expectations for its end markets, and a live audio webcast will be accessible via the company’s investor relations website, signaling ongoing engagement with the investment community and transparency around its outlook.

The most recent analyst rating on (UNH) stock is a Buy with a $340.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.

UnitedHealth Realigns Finance Leadership, Appoints New Accounting Chief

UnitedHealth Group said its board appointed Dennis Stankiewicz, 48, as Chief Accounting Officer effective March 2, 2026, while he continues in his role as Corporate Controller, which he has held since April 17, 2023. Stankiewicz, who joined the company in 2016 after a partnership at Deloitte & Touche and has more than 24 years of experience, will receive a $550,000 base salary, performance-based cash and equity incentives aligned with his responsibilities, and severance equal to one year of salary if terminated without cause, contingent on non-compete obligations.

The company noted that Stankiewicz has no related-party transactions requiring disclosure, underscoring a clean governance profile for the new appointee. Concurrently, Tom Roos, Chief Accounting Officer since August 2015, will shift to become Chief Financial Officer of Optum Insight on March 2, 2026, signaling a broader realignment of senior finance leadership across UnitedHealth’s core business and its data and technology-focused Optum unit.

The most recent analyst rating on (UNH) stock is a Buy with a $340.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.

UnitedHealth Tightens Executive Stock Option Holding Requirements

On February 23, 2026, UnitedHealth Group’s Compensation and Human Resources Committee amended a stock option granted to executive Stephen Hemsley on May 14, 2025. The change imposes a two-year share holding requirement after the existing three-year cliff vesting, obliging him to retain any net shares from exercising the option until May 14, 2030, with other terms unchanged.

The added holding period underscores a stronger alignment between executive equity incentives and long-term shareholder interests. By extending the time frame in which Hemsley must hold shares, the company reinforces long-horizon performance focus and may signal to investors an emphasis on sustained value creation rather than short-term stock gains.

The most recent analyst rating on (UNH) stock is a Buy with a $350.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.

UnitedHealth Reaffirms 2025 EPS Outlook to Investors

On January 12, 2026, UnitedHealth Group’s senior management planned to meet with investors to discuss the company’s outlook and operations. During these meetings, management intended to reaffirm the company’s previously disclosed adjusted 2025 earnings per share expectations, while cautioning that full-year 2025 financial closing procedures were still in progress and that final results could differ from the indicated ranges once reviews and final adjustments are completed.

The most recent analyst rating on (UNH) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.